Here, we present a patient with a malignant PXA with a BRAF V600E mutation, who had a prolonged response to BRAF MEKi and benefited by the addition of chloroquine with an ongoing prolonged disease control. The gene discussed is BRAF; the disease is pleomorphic xanthoastrocytoma.